EC Approves Daraxonrasib for Metastatic Pancreatic Cancer via Fast Track

European health regulators have approved daraxonrasib as a new treatment for metastatic pancreatic cancer, giving patients an average overall survival of 12.4 months compared to standard chemotherapy.

The European Commission approved the pill on Tuesday through an accelerated procedure, according to reporting by HLN. The European Medicines Agency reviewed the dossier in just over 100 days, roughly twice as fast as the previous 210-day statutory timeframe. The treatment was developed by the American start-up Revolution Medicines and gained approval in the United States over the summer.

Pancreatic cancer is one of the deadliest malignancies, frequently diagnosed only in advanced stages after metastasis has occurred. In the Netherlands, approximately 3,300 individuals receive the diagnosis annually, with the vast majority succumbing to the disease within twelve months, rtl.nl reported.

“Dit onderzoek was voor mensen met uitgezaaide kanker die niet meer reageren op standaard chemotherapie. Zij zijn niet te genezen,” said Marc Besselink, a surgeon at Amsterdam UMC, as reported by rtl.nl.

Daraxonrasib Extends Survival to 12.4 Months

  • Mechanism of Action: Daraxonrasib is an targeted oral pill administered in tablet forms to adult patients who have previously undergone standard chemotherapy regimens.
  • Efficacy Metrics: Clinical trial data showed that trial participants lived an average of 12.4 months, outperforming the 6.7-month average seen with standard chemotherapy alone.
  • Tumor Response: In a separate trial group, the agent halted tumor growth in nearly all participants, shrank tumors in about one-third, and rendered them undetectable on scans in under 10 percent.

International Study Shows Survival Improvement with Daraxonrasib

International study results indicate that patients receiving daraxonrasib after standard chemotherapy achieved an average survival duration of 12.4 months. Patients managed solely on chemotherapy reached an average survival of 6.7 months.

Besselink described the clinical outcomes as extraordinarily remarkable, noting that tumor progression halted in virtually all trial participants. He cautioned, however, that the medication does not offer a cure for aggressive metastatic disease.

“Echt ongelofelijk bijzonder,” Besselink told rtl.nl, characterizing the findings while emphasizing that the research represents only an initial step toward broader therapeutic applications.

Access and Pricing Challenges in Europe

Despite the fast-tracked European approval, Dutch patients cannot yet obtain the medication through standard prescriptions. Access barriers remain tied to institutional procurement timelines and high financial costs.

The annual treatment cost per patient reaches approximately 450,000 euros. Besselink said that while administrative processes take time, wider availability is anticipated.

“Het is afwachten wanneer het beschikbaar wordt, maar dat gaat zeker gebeuren,” Besselink told rtl.nl.

Concurrently, research infrastructure continues to expand across Europe. A specialized team at Erasmus MC worked on developing a therapeutic vaccine targeting pancreatic cancer, adding to ongoing oncological investigations.

Drug Approved Only for Previously Treated Metastatic Patients

Daraxonrasib is strictly indicated for adult patients with advanced metastatic pancreatic cancer who have previously failed standard chemotherapy regimens. The drug is not authorized for newly diagnosed, localized, or treatment-naive cases. Because pancreatic cancer exhibits few early symptoms and metastasizes rapidly to surrounding organs, individuals experiencing persistent abdominal pain, unexplained weight loss, or jaundice should consult a physician immediately for diagnostic imaging.

Future Outlook

Medical investigators are evaluating how to adapt daraxonrasib for broader patient demographics and earlier intervention stages. Regulatory bodies continue to monitor post-marketing safety data following the expedited green light from Brussels.

The European Commission, the EU’s executive cabinet, traces its roots to the 1951 High Authority of the European Coal and Steel Community, which took office in Luxembourg City on 10 August 1952 under President Jean Monnet.

The modern Commission emerged on 1 July 1967 when the Merger Treaty fused the three European Executives into a single administration under President Jean Rey. Today it comprises 27 commissioners — one per member state — supported by roughly 32,000 civil servants organised into Directorates-General that function like national ministries.

“Pancreas kanker is einde verhaal en het moet gaan om elke kealitatieve dag tussen diagnose en dood,” remarked Marc Vinck, as cited by HLN.

References

  • HLN News Coverage: Europese Commissie keurt nieuwe behandeling voor uitgezaaide pancreaskanker goed
  • RTL.nl Health Reporting: Nieuw medicijn tegen alvleesklierkanker ‘grote doorbraak’ voor patiënten
  • European Medicines Agency (EMA) Assessment Summaries
Photo of author

Health Desk

Health Desk at Archyde.

Central Weather Administration Warns Coldest Morning Saturday, Snow Possible on High Peaks

Seattle Times: Trump Projects Power Abroad While Forced to Share It at Home